Akebia Therapeutics, Inc. AKBA
Set alert
At close · Oct 30
After hours · Oct 30, 6:55 PM ET
- YTD
- -56.12%
- 1 year
- -66.36%
- Open
- 0.721
- Prev close
- 0.7422
- Mkt cap
- 195.78M
- Vol
- 2.78M
- Avg vol
- 7.84M
- EPS
- -0.12
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.6951
- High
- 0.7348
- Forward P/E
- -7.15
- Beta
- 0.73
- Short ratio
- 4.71
- Inst. own
- 27.33%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.80
- 200-d avg
- 1.45
- 1y target
- 5.50
5D chart
Signals (125)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:50 PM | 2 days ago |
| RSI: Oversold | Oct 30, 3:25 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 3:15 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:05 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:20 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 2:20 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:40 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:25 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:10 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:25 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:20 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:15 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:05 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 3:55 PM | 3 days ago |
| RSI: Oversold | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:25 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:20 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:25 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 11:50 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:55 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:45 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:15 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:50 AM | 3 days ago |
| RSI: Overbought | Oct 28, 3:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:55 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:45 PM | 4 days ago |
| RSI: Overbought | Oct 28, 1:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 11:55 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:50 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:20 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:15 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:15 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:10 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:05 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:35 AM | 4 days ago |
| RSI: Overbought | Oct 28, 10:15 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:10 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:00 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:55 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 3:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:15 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:00 PM | 6 days ago |
| RSI: Overbought | Oct 26, 12:20 PM | 6 days ago |
| RSI: Overbought | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:05 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:00 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:50 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:40 AM | 6 days ago |
News
3 days ago globenewswire.com
Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights
WALTHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2026, on…
6 days ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
-
6 days ago benzinga.com
Akebia Therapeutics Reports Data From Vafseo Outcomes In Center Experience Study At American Society Of Nephrology Kidney Week 2026 In Patients With Treated With Vadadustat
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease announced that U.S. Renal Care (USRC), the nation’s…
6 days ago globenewswire.com
U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week
Vadadustat demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Vadadustat demonstrated a clinically meaningful…
3 weeks ago globenewswire.com
Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,…
3 weeks ago globenewswire.com
Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia's Rare Kidney Pipeline at ASN Kidney Week 2026
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,…
1 month ago globenewswire.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,…
-
1 month ago benzinga.com
BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target
BTIG analyst Julian Harrison reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $4 price target.
-
1 month ago benzinga.com
Akebia Therapeutics Doses First Patient In Phase 2 Basket Trial Of Ebribafusp In Rare Complement-Mediated Kidney Diseases
Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathyInitial data is expected in 2027
1 month ago globenewswire.com
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy Initial data is expected in 2027 WALTHAM, Mass., Sept. 14, 2026 (GLOBE…
-
1 month ago benzinga.com
WestPark Capital Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $4.5
WestPark Capital analyst Ed Arce initiates coverage on Akebia Therapeutics (NASDAQ:AKBA) with a Buy rating and announces Price Target of $4.5.
2 months ago globenewswire.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney…
2 months ago globenewswire.com
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's pre-market session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
2 months ago benzinga.com
Western Digital, Applovin, Zillow Group And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures mixed, Dow up 100+ points. Western Digital falls after earnings beat expectations but lowers guidance. Other stocks dip in pre-market.
2 months ago benzinga.com
Why SiTime Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
SiTime Corp (SITM) stock rose 30.7% in pre-market trading after beating earnings and sales estimates. Other gainers include CLRO, WYHG, SURG, PAVS, MGRX, CELZ, SOUN, WPP, HNST. YXT was the only loser…
2 months ago seekingalpha.com
Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call Transcript
Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call Transcript
2 months ago zacks.com
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to break-even earnings per share a year ago.
2 months ago marketbeat.com
Akebia Therapeutics Q2 Earnings Call Highlights
Akebia Therapeutics NASDAQ: AKBA reported second-quarter revenue growth for its Vafseo anemia treatment while highlighting an interim clinical result from the VOICE study and progress across its…
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday's after-market session. The company's market cap stands at $4.2 million. Caris Life Sciences…
2 months ago globenewswire.com
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Q2 2026 Vafseo® (vadadustat) net product revenues grew to $21.3 million ; more than 10,500 p atients now on therapy Advancement of rare kidney disease pipeline continues with initiation of Phase 2…
3 months ago globenewswire.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,…
3 months ago globenewswire.com
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,…
3 months ago globenewswire.com
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
CAMBRIDGE, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2026 on…
4 months ago globenewswire.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,…
4 months ago globenewswire.com
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Primary Investigator to stop trial on…
4 months ago globenewswire.com
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
CAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,…
5 months ago marketbeat.com
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near
Akebia Therapeutics NASDAQ: AKBA outlined its commercial priorities for Vafseo, the expected evolution of reimbursement after the TDAPA period and several renal-disease pipeline programs during a…
5 months ago globenewswire.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,…
8 months ago benzinga.com
Earnings Scheduled For February 26, 2026
Earnings Scheduled For February 26, 2026
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
11 months ago benzinga.com
Earnings Scheduled For November 10, 2025
Earnings Scheduled For November 10, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
1 year ago benzinga.com
Mondelez International, Stride, Varonis Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Mondelez International, Stride, Varonis Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
1 year ago benzinga.com
Why Teradyne Shares Are Trading Higher By More Than 20%; Here Are 20 Stocks Moving Premarket
Why Teradyne Shares Are Trading Higher By More Than 20%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
2 years ago benzinga.com
Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Shares of RH (NYSE: RH) rose sharply in today’s pre-market trading following the release of quarterly results.
-
2 years ago benzinga.com
Earnings Scheduled For March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.
-
2 years ago benzinga.com
Earnings Scheduled For November 8, 2023
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.
-
3 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session